25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

S49 (Supernus) Stock Analysis
Buy, Hold or Sell?

Let's analyze Supernus together

I guess you are interested in Supernus Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Supernus’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Supernus’s Price Targets

I'm going to help you getting a better view of Supernus Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Supernus Pharmaceuticals Inc

I send you an email if I find something interesting about Supernus Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Supernus (30 sec.)










1.2. What can you expect buying and holding a share of Supernus? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€16.36
Expected worth in 1 year
€18.17
How sure are you?
97.0%

+ What do you gain per year?

Total Gains per Share
€1.80
Return On Investment
6.5%

For what price can you sell your share?

Current Price per Share
€27.80
Expected price per share
€25.00 - €30.80
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Supernus (5 min.)




Live pricePrice per Share (EOD)
€27.80
Intrinsic Value Per Share
€12.44 - €14.07
Total Value Per Share
€28.81 - €30.43

2.2. Growth of Supernus (5 min.)




Is Supernus growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$916.4m$65.9m6.7%

How much money is Supernus making?

Current yearPrevious yearGrowGrow %
Making money$18.4m$328.9k$18.1m98.2%
Net Profit Margin10.7%0.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Supernus (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Supernus?

Welcome investor! Supernus's management wants to use your money to grow the business. In return you get a share of Supernus.

First you should know what it really means to hold a share of Supernus. And how you can make/lose money.

Speculation

The Price per Share of Supernus is €27.80. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Supernus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Supernus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €16.36. Based on the TTM, the Book Value Change Per Share is €0.45 per quarter. Based on the YOY, the Book Value Change Per Share is €0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Supernus.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps0.271.0%0.331.2%-0.07-0.3%0.271.0%0.321.2%
Usd Book Value Change Per Share0.511.8%0.511.8%0.160.6%0.391.4%0.562.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.511.8%0.511.8%0.160.6%0.391.4%0.562.0%
Usd Price Per Share40.37-33.68-32.15-29.85-32.68-
Price to Earnings Ratio36.75-1,005.95--206.14-195.07-128.33-
Price-to-Total Gains Ratio78.84-106.48-66.80-96.46-86.49-
Price to Book Ratio2.18-1.91-1.96-1.96-3.67-
Price-to-Total Gains Ratio78.84-106.48-66.80-96.46-86.49-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share31.5252
Number of shares31
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.510.39
Usd Total Gains Per Share0.510.39
Gains per Quarter (31 shares)15.8612.23
Gains per Year (31 shares)63.4348.91
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10635304939
2012711609888
301901790147137
402542420196186
503173050245235
603813680293284
704444310342333
805074940391382
905715570440431
1006346200489480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%9.03.00.075.0%17.03.00.085.0%30.03.00.090.9%30.03.00.090.9%
Book Value Change Per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%32.01.00.097.0%32.01.00.097.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.033.00.0%0.00.033.00.0%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%32.01.00.097.0%32.01.00.097.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Supernus Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4520.451+0%0.139+224%0.348+30%0.496-9%
Book Value Per Share--16.36315.520+5%14.479+13%13.353+23%10.448+57%
Current Ratio--2.3462.047+15%1.537+53%1.920+22%2.197+7%
Debt To Asset Ratio--0.2430.263-8%0.337-28%0.422-42%0.438-45%
Debt To Equity Ratio--0.3210.358-10%0.541-41%0.791-59%0.836-62%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--1693938788.0001348798314.500+26%1145414686.250+48%903876615.390+87%1137239801.985+49%
Eps--0.2420.292-17%-0.065+127%0.236+3%0.284-15%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--2.7582.328+18%2.151+28%1.660+66%2.960-7%
Free Cash Flow Per Share--0.6980.676+3%0.437+60%0.520+34%0.520+34%
Free Cash Flow To Equity Per Share--0.7910.724+9%-3.343+523%-0.335+142%-0.335+142%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--14.071--------
Intrinsic Value_10Y_min--12.443--------
Intrinsic Value_1Y_max--2.000--------
Intrinsic Value_1Y_min--1.965--------
Intrinsic Value_3Y_max--5.560--------
Intrinsic Value_3Y_min--5.317--------
Intrinsic Value_5Y_max--8.578--------
Intrinsic Value_5Y_min--8.000--------
Market Cap1551643100.000-28%1986996200.0001657690650.000+20%1582341075.000+26%1469316712.500+35%1608284669.409+24%
Net Profit Margin--0.0880.107-17%0.002+4644%0.108-18%0.163-46%
Operating Margin----0%-0.0310%0.122-100%0.219-100%
Operating Ratio--1.0251.010+1%1.123-9%0.989+4%0.832+23%
Pb Ratio1.699-28%2.1761.912+14%1.959+11%1.962+11%3.674-41%
Pe Ratio28.700-28%36.7521005.951-96%-206.142+661%195.066-81%128.335-71%
Price Per Share27.800-28%35.60029.700+20%28.350+26%26.325+35%28.815+24%
Price To Free Cash Flow Ratio9.954-28%12.74711.200+14%2.238+470%15.001-15%9.091+40%
Price To Total Gains Ratio61.562-28%78.835106.478-26%66.801+18%96.462-18%86.491-9%
Quick Ratio--1.8001.560+15%0.862+109%1.115+61%1.204+50%
Return On Assets--0.0110.014-19%-0.001+106%0.011+6%0.019-42%
Return On Equity--0.0150.018-20%0.000+4016%0.020-26%0.036-59%
Total Gains Per Share--0.4520.451+0%0.139+224%0.348+30%0.496-9%
Usd Book Value--1035692813.560982337633.821+5%916405692.080+13%845146507.043+23%661273493.108+57%
Usd Book Value Change Per Share--0.5120.512+0%0.158+224%0.394+30%0.562-9%
Usd Book Value Per Share--18.55617.600+5%16.419+13%15.142+23%11.848+57%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--1920926585.5921529537288.643+26%1298900254.208+48%1024996081.852+87%1289629935.451+49%
Usd Eps--0.2750.331-17%-0.074+127%0.267+3%0.323-15%
Usd Free Cash Flow--44191285.31242804839.108+3%27632427.820+60%32909023.080+34%19944862.473+122%
Usd Free Cash Flow Per Share--0.7920.767+3%0.495+60%0.590+34%0.590+34%
Usd Free Cash Flow To Equity Per Share--0.8970.822+9%-3.791+523%-0.380+142%-0.380+142%
Usd Market Cap1759563275.400-28%2253253690.8001879821197.100+20%1794374779.050+26%1666205151.975+35%1823794815.110+24%
Usd Price Per Share31.525-28%40.37033.680+20%32.149+26%29.853+35%32.676+24%
Usd Profit--15327405.27418465533.510-17%328987.235+4559%15812686.444-3%18542250.230-17%
Usd Revenue--174152242.631165447830.375+5%151874357.046+15%151831508.709+15%127359058.277+37%
Usd Total Gains Per Share--0.5120.512+0%0.158+224%0.394+30%0.562-9%
 EOD+4 -4MRQTTM+24 -11YOY+31 -45Y+28 -810Y+20 -16

3.3 Fundamental Score

Let's check the fundamental score of Supernus Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1528.700
Price to Book Ratio (EOD)Between0-11.699
Net Profit Margin (MRQ)Greater than00.088
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.800
Current Ratio (MRQ)Greater than12.346
Debt to Asset Ratio (MRQ)Less than10.243
Debt to Equity Ratio (MRQ)Less than10.321
Return on Equity (MRQ)Greater than0.150.015
Return on Assets (MRQ)Greater than0.050.011
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Supernus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.735
Ma 20Greater thanMa 5029.190
Ma 50Greater thanMa 10031.384
Ma 100Greater thanMa 20033.454
OpenGreater thanClose27.800
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Fundamental data was last updated by Penke on 2025-04-10 06:50:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Supernus earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Supernus to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 8.8%Β means thatΒ €0.09 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 8.8%. The company is making a profit. +1
  • The TTM is 10.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ8.8%TTM10.7%-1.9%
TTM10.7%YOY0.2%+10.5%
TTM10.7%5Y10.8%-0.1%
5Y10.8%10Y16.3%-5.5%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Supernus is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Supernus to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 1.1% Return on Assets means thatΒ Supernus generatedΒ €0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 1.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.1%TTM1.4%-0.3%
TTM1.4%YOY-0.1%+1.4%
TTM1.4%5Y1.1%+0.3%
5Y1.1%10Y1.9%-0.9%
4.3.1.3. Return on Equity

Shows how efficient Supernus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Supernus to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 1.5% Return on Equity means Supernus generated €0.01Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 1.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.5%TTM1.8%-0.4%
TTM1.8%YOY0.0%+1.8%
TTM1.8%5Y2.0%-0.1%
5Y2.0%10Y3.6%-1.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Supernus Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Supernus is operatingΒ .

  • Measures how much profit Supernus makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Supernus to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-3.1%+3.1%
TTM-5Y12.2%-12.2%
5Y12.2%10Y21.9%-9.7%
4.3.2.2. Operating Ratio

Measures how efficient Supernus is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.02 means that the operating costs are €1.02 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 1.025. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.010. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.025TTM1.010+0.015
TTM1.010YOY1.123-0.113
TTM1.0105Y0.989+0.021
5Y0.98910Y0.832+0.158
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Supernus Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Supernus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.35Β means the company has €2.35 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 2.346. The company is able to pay all its short-term debts. +1
  • The TTM is 2.047. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.346TTM2.047+0.300
TTM2.047YOY1.537+0.510
TTM2.0475Y1.920+0.127
5Y1.92010Y2.197-0.277
4.4.3.2. Quick Ratio

Measures if Supernus is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Supernus to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.80Β means the company can pay off €1.80 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 1.800. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.560. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.800TTM1.560+0.241
TTM1.560YOY0.862+0.698
TTM1.5605Y1.115+0.444
5Y1.11510Y1.204-0.089
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Supernus Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of SupernusΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Supernus to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.24Β means that Supernus assets areΒ financed with 24.3% credit (debt) and the remaining percentage (100% - 24.3%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 0.243. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.263. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.243TTM0.263-0.020
TTM0.263YOY0.337-0.074
TTM0.2635Y0.422-0.159
5Y0.42210Y0.438-0.016
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Supernus is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Supernus to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 32.1% means that company has €0.32 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Supernus Pharmaceuticals Inc:

  • The MRQ is 0.321. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.358. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.321TTM0.358-0.037
TTM0.358YOY0.541-0.183
TTM0.3585Y0.791-0.433
5Y0.79110Y0.836-0.046
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Supernus generates.

  • Above 15 is considered overpriced butΒ always compareΒ Supernus to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 36.75 means the investor is paying €36.75Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Supernus Pharmaceuticals Inc:

  • The EOD is 28.700. Based on the earnings, the company is overpriced. -1
  • The MRQ is 36.752. Based on the earnings, the company is overpriced. -1
  • The TTM is 1,005.951. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD28.700MRQ36.752-8.052
MRQ36.752TTM1,005.951-969.198
TTM1,005.951YOY-206.142+1,212.092
TTM1,005.9515Y195.066+810.885
5Y195.06610Y128.335+66.731
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Supernus Pharmaceuticals Inc:

  • The EOD is 9.954. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 12.747. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 11.200. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD9.954MRQ12.747-2.793
MRQ12.747TTM11.200+1.547
TTM11.200YOY2.238+8.962
TTM11.2005Y15.001-3.800
5Y15.00110Y9.091+5.909
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Supernus is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.18 means the investor is paying €2.18Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Supernus Pharmaceuticals Inc:

  • The EOD is 1.699. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.176. Based on the equity, the company is underpriced. +1
  • The TTM is 1.912. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.699MRQ2.176-0.477
MRQ2.176TTM1.912+0.263
TTM1.912YOY1.959-0.046
TTM1.9125Y1.962-0.049
5Y1.96210Y3.674-1.713
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,368,073
Total Liabilities332,340
Total Stockholder Equity1,035,733
 As reported
Total Liabilities 332,340
Total Stockholder Equity+ 1,035,733
Total Assets = 1,368,073

Assets

Total Assets1,368,073
Total Current Assets686,070
Long-term Assets682,003
Total Current Assets
Cash And Cash Equivalents 69,331
Short-term Investments 384,281
Net Receivables 142,077
Inventory 54,293
Other Current Assets 36,088
Total Current Assets  (as reported)686,070
Total Current Assets  (calculated)686,070
+/-0
Long-term Assets
Property Plant Equipment 11,545
Goodwill 117,019
Intangible Assets 521,912
Long-term Assets Other 31,527
Long-term Assets  (as reported)682,003
Long-term Assets  (calculated)682,003
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities292,397
Long-term Liabilities39,943
Total Stockholder Equity1,035,733
Total Current Liabilities
Accounts payable 4,587
Other Current Liabilities 47,340
Total Current Liabilities  (as reported)292,397
Total Current Liabilities  (calculated)51,927
+/- 240,470
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt34,271
Long-term Liabilities Other 7,600
Long-term Liabilities  (as reported)39,943
Long-term Liabilities  (calculated)41,871
+/- 1,928
Total Stockholder Equity
Retained Earnings 556,426
Total Stockholder Equity (as reported)1,035,733
Total Stockholder Equity (calculated)556,426
+/- 479,307
Other
Capital Stock56
Common Stock Shares Outstanding 55,743
Net Invested Capital 1,035,733
Net Working Capital 393,673
Property Plant and Equipment Gross 29,388



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
309,568
322,256
346,370
385,478
424,464
825,160
852,799
922,512
977,811
1,025,448
1,063,675
1,106,909
1,160,282
1,189,866
1,491,020
1,510,022
1,504,102
1,507,443
1,573,060
1,555,040
1,689,152
1,639,517
1,694,973
1,693,129
1,702,508
1,791,808
1,293,099
1,285,160
1,277,673
1,304,090
1,315,829
1,342,701
1,368,073
1,368,0731,342,7011,315,8291,304,0901,277,6731,285,1601,293,0991,791,8081,702,5081,693,1291,694,9731,639,5171,689,1521,555,0401,573,0601,507,4431,504,1021,510,0221,491,0201,189,8661,160,2821,106,9091,063,6751,025,448977,811922,512852,799825,160424,464385,478346,370322,256309,568
   > Total Current Assets 
151,404
149,757
165,492
191,330
228,451
583,246
284,516
390,557
493,487
419,967
390,911
427,082
472,644
557,048
557,153
552,015
630,417
586,023
639,244
668,375
601,590
568,516
625,120
663,886
734,151
883,340
423,538
449,360
493,113
544,321
591,002
640,003
686,070
686,070640,003591,002544,321493,113449,360423,538883,340734,151663,886625,120568,516601,590668,375639,244586,023630,417552,015557,153557,048472,644427,082390,911419,967493,487390,557284,516583,246228,451191,330165,492149,757151,404
       Cash And Cash Equivalents 
66,398
59,599
61,737
81,924
100,304
444,140
35,205
123,818
192,248
122,778
87,344
116,889
181,381
225,767
210,975
204,293
288,640
255,642
223,771
215,281
203,434
115,715
173,428
111,492
93,120
58,442
24,706
94,985
75,054
63,401
52,089
31,673
69,331
69,33131,67352,08963,40175,05494,98524,70658,44293,120111,492173,428115,715203,434215,281223,771255,642288,640204,293210,975225,767181,381116,88987,344122,778192,248123,81835,205444,140100,30481,92461,73759,59966,398
       Short-term Investments 
23,723
27,533
31,229
32,626
39,736
45,585
139,208
156,407
163,770
170,165
171,222
179,808
165,692
175,104
163,839
147,657
133,893
135,459
186,070
228,571
136,246
196,485
187,359
280,297
368,214
170,126
126,950
105,204
179,820
234,335
295,098
371,537
384,281
384,281371,537295,098234,335179,820105,204126,950170,126368,214280,297187,359196,485136,246228,571186,070135,459133,893147,657163,839175,104165,692179,808171,222170,165163,770156,407139,20845,58539,73632,62631,22927,53323,723
       Net Receivables 
41,527
38,885
51,157
56,166
65,586
67,864
74,842
77,753
102,922
79,950
84,564
86,699
87,332
119,195
126,559
133,107
140,877
127,065
137,275
133,676
148,932
145,149
158,063
164,086
165,497
143,568
136,556
141,764
144,155
147,734
152,494
145,408
142,077
142,077145,408152,494147,734144,155141,764136,556143,568165,497164,086158,063145,149148,932133,676137,275127,065140,877133,107126,559119,19587,33286,69984,56479,950102,92277,75374,84267,86465,58656,16651,15738,88541,527
       Inventory 
16,801
19,167
16,623
14,947
16,304
19,075
20,680
23,280
25,659
26,518
26,024
25,504
26,628
24,418
35,338
42,465
48,325
50,226
58,391
60,155
85,959
88,795
84,860
83,165
91,541
91,147
90,560
83,480
77,408
75,079
68,155
63,981
54,293
54,29363,98168,15575,07977,40883,48090,56091,14791,54183,16584,86088,79585,95960,15558,39150,22648,32542,46535,33824,41826,62825,50426,02426,51825,65923,28020,68019,07516,30414,94716,62319,16716,801
       Other Current Assets 
2,955
4,573
4,746
5,667
6,521
6,582
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,019
22,372
21,410
24,846
15,779
403,758
44,766
23,927
16,676
23,772
23,166
27,404
36,088
36,08827,40423,16623,77216,67623,92744,766403,75815,77924,84621,41022,37227,019000000000000006,5826,5215,6674,7464,5732,955
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
605,481
672,764
679,827
687,638
632,818
933,867
958,007
873,685
921,420
933,816
886,665
1,087,562
1,071,001
1,069,853
1,029,243
968,357
908,468
869,561
835,800
784,560
759,769
724,827
702,698
682,003
682,003702,698724,827759,769784,560835,800869,561908,468968,3571,029,2431,069,8531,071,0011,087,562886,665933,816921,420873,685958,007933,867632,818687,638679,827672,764605,481000000000
       Property Plant Equipment 
4,344
4,342
4,572
4,688
5,124
5,003
4,897
6,930
4,095
24,275
23,667
28,757
38,347
39,922
61,709
60,090
58,055
58,758
46,730
46,579
52,320
49,356
46,953
15,872
15,173
14,611
14,186
13,688
13,530
12,969
12,274
11,876
11,545
11,54511,87612,27412,96913,53013,68814,18614,61115,17315,87246,95349,35652,32046,57946,73058,75858,05560,09061,70939,92238,34728,75723,66724,2754,0956,9304,8975,0035,1244,6884,5724,3424,344
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
88,095
89,143
77,911
77,911
77,963
77,963
117,516
115,414
115,414
117,383
117,019
117,019
117,019
117,019
117,019
117,019
117,019
117,019
117,019
117,019117,019117,019117,019117,019117,019117,019117,019117,019117,383115,414115,414117,51677,96377,96377,91177,91189,14388,09500000000000000
       Long Term Investments 
75,410
89,163
104,632
123,123
133,638
175,064
503,312
460,304
418,798
522,551
593,754
596,442
591,773
534,712
358,673
388,185
350,359
416,566
445,473
405,479
119,166
125,337
147,373
131,937
93,896
54,157
37,478
25,125
16,617
11,662
0
0
0
00011,66216,61725,12537,47854,15793,896131,937147,373125,337119,166405,479445,473416,566350,359388,185358,673534,712591,773596,442593,754522,551418,798460,304503,312175,064133,638123,123104,63289,16375,410
       Intangible Assets 
16,490
29,450
28,989
37,162
36,019
34,858
33,794
32,572
31,368
30,063
28,787
26,101
24,840
23,579
408,272
402,265
442,253
358,736
352,628
346,619
784,693
764,049
743,405
722,761
702,463
682,497
662,389
641,147
599,889
579,752
559,644
540,156
521,912
521,912540,156559,644579,752599,889641,147662,389682,497702,463722,761743,405764,049784,693346,619352,628358,736442,253402,265408,27223,57924,84026,10128,78730,06331,36832,57233,79434,85836,01937,16228,98929,45016,490
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
625
581
574
615
538
17,118
18,324
43,249
30,257
40,687
40,133
49,232
48,986
47,344
41,290
39,806
40,184
38,489
38,821
37,505
38,367
35,890
33,647
31,527
31,52733,64735,89038,36737,50538,82138,48940,18439,80641,29047,34448,98649,23240,13340,68730,25743,24918,32417,118538615574581625000000000
> Total Liabilities 
117,813
116,192
116,973
133,815
156,984
473,291
462,307
500,576
524,788
545,430
540,771
549,652
564,854
576,483
825,046
801,143
759,244
752,999
787,481
744,572
873,301
811,071
853,539
840,331
816,304
879,658
373,191
372,969
356,157
374,924
358,375
335,551
332,340
332,340335,551358,375374,924356,157372,969373,191879,658816,304840,331853,539811,071873,301744,572787,481752,999759,244801,143825,046576,483564,854549,652540,771545,430524,788500,576462,307473,291156,984133,815116,973116,192117,813
   > Total Current Liabilities 
80,742
82,003
85,524
104,956
123,000
119,088
103,934
138,346
161,353
151,706
143,971
149,717
160,587
168,335
269,276
299,606
245,108
240,812
283,447
234,711
315,379
284,558
735,536
725,987
687,958
731,545
252,590
287,534
290,196
314,554
308,656
291,508
292,397
292,397291,508308,656314,554290,196287,534252,590731,545687,958725,987735,536284,558315,379234,711283,447240,812245,108299,606269,276168,335160,587149,717143,971151,706161,353138,346103,934119,088123,000104,95685,52482,00380,742
       Short-term Debt 
0
3,310
1,472
0
0
318,225
321,920
0
0
3,250
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000003,25000321,920318,225001,4723,3100
       Short Long Term Debt 
0
3,310
1,472
0
0
318,225
321,920
0
0
3,250
0
0
0
0
0
0
0
0
0
0
0
0
400,909
401,438
401,968
480,863
0
0
0
0
0
0
0
0000000480,863401,968401,438400,9090000000000003,25000321,920318,225001,4723,3100
       Accounts payable 
80,533
81,716
7,577
6,262
6,844
3,333
2,943
9,838
3,195
7,240
4,081
3,090
10,141
3,124
5,515
11,193
6,147
5,954
7,229
9,125
9,331
12,323
35,518
16,015
10,543
11,544
83,044
3,389
1,964
14,397
4,628
6,392
4,587
4,5876,3924,62814,3971,9643,38983,04411,54410,54316,01535,51812,3239,3319,1257,2295,9546,14711,1935,5153,12410,1413,0904,0817,2403,1959,8382,9433,3336,8446,2627,57781,71680,533
       Other Current Liabilities 
209
287
54,513
71,802
88,851
90,731
71,703
96,410
36,620
2,426
2,668
2,959
24,505
37,596
78,847
114,228
65,824
75,142
62,736
63,789
100,099
90,178
92,979
95,085
82,991
56,525
169,546
46,590
56,353
60,926
50,926
46,581
47,340
47,34046,58150,92660,92656,35346,590169,54656,52582,99195,08592,97990,178100,09963,78962,73675,14265,824114,22878,84737,59624,5052,9592,6682,42636,62096,41071,70390,73188,85171,80254,513287209
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
393,724
396,800
399,935
404,267
408,148
555,770
501,537
514,136
512,187
504,034
509,861
557,922
526,513
118,003
114,344
128,346
148,113
120,601
85,435
65,961
60,370
49,719
44,043
39,943
39,94344,04349,71960,37065,96185,435120,601148,113128,346114,344118,003526,513557,922509,861504,034512,187514,136501,537555,770408,148404,267399,935396,800393,724000000000
       Capital Lease Obligations Min Short Term Debt
0
-3,310
-1,472
0
0
-318,225
-321,920
0
0
27,824
30,892
30,401
33,265
34,260
56,251
56,164
28,579
28,532
36,143
37,261
47,775
46,032
37,080
36,028
35,998
36,511
42,196
42,321
41,527
42,127
39,977
38,153
34,271
34,27138,15339,97742,12741,52742,32142,19636,51135,99836,02837,08046,03247,77537,26136,14328,53228,57956,16456,25134,26033,26530,40130,89227,82400-321,920-318,22500-1,472-3,3100
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
32,590
32,055
31,516
28,657
28,112
118,215
57,264
88,591
85,875
64,522
63,666
52,017
23,397
21,610
20,152
42,539
61,934
42,124
16,370
7,802
7,875
7,985
7,753
7,600
7,6007,7537,9857,8757,80216,37042,12461,93442,53920,15221,61023,39752,01763,66664,52285,87588,59157,264118,21528,11228,65731,51632,05532,590000000000
       Deferred Long Term Liability 
1,501
1,365
11,887
1,221
1,149
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000001,1491,22111,8871,3651,501
> Total Stockholder Equity
191,755
206,064
229,397
251,663
267,480
351,869
390,492
421,936
453,023
480,018
522,904
557,257
595,428
613,383
665,974
708,879
744,858
754,444
785,579
810,468
815,851
828,446
841,434
852,798
886,204
912,150
919,908
912,191
921,516
929,166
957,454
1,007,150
1,035,733
1,035,7331,007,150957,454929,166921,516912,191919,908912,150886,204852,798841,434828,446815,851810,468785,579754,444744,858708,879665,974613,383595,428557,257522,904480,018453,023421,936390,492351,869267,480251,663229,397206,064191,755
   Common Stock
50
50
51
51
51
52
52
52
52
52
52
52
53
53
53
53
53
53
53
53
53
53
53
54
54
0
55
0
0
0
0
0
0
00000055054545353535353535353535353525252525252525151515050
   Retained Earnings Total Equity000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000
   Other Stockholders Equity 
-134
32
216
252
-747
-2,291
-4,119
-4,111
-3,158
1,427
5,924
7,261
7,417
-166
11,359
9,700
8,975
6,249
5,433
4,209
1,539
-773
-2,220
-4,046
-3,210
0
-1,775
0
0
0
0
0
0
000000-1,7750-3,210-4,046-2,220-7731,5394,2095,4336,2498,9759,70011,359-1667,4177,2615,9241,427-3,158-4,111-4,119-2,291-74725221632-134



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue661,817
Cost of Revenue-77,906
Gross Profit583,911583,911
 
Operating Income (+$)
Gross Profit583,911
Operating Expense-586,261
Operating Income75,556-2,350
 
Operating Expense (+$)
Research Development108,796
Selling General Administrative321,582
Selling And Marketing Expenses-
Operating Expense586,261430,378
 
Net Interest Income (+$)
Interest Income16,204
Interest Expense-0
Other Finance Cost-0
Net Interest Income16,204
 
Pretax Income (+$)
Operating Income75,556
Net Interest Income16,204
Other Non-Operating Income Expenses-
Income Before Tax (EBT)97,87069,446
EBIT - interestExpense = 0
73,865
73,865
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-97,870
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax97,870
Tax Provision-24,005
Net Income From Continuing Ops73,86573,865
Net Income73,865
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net6,110-16,204
 

Technical Analysis of Supernus
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Supernus. The general trend of Supernus is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Supernus's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Supernus Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Supernus Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 30.60 < 30.80 < 30.80.

The bearish price targets are: 26.80 > 25.20 > 25.00.

Know someone who trades $S49? Share this with them.πŸ‘‡

Supernus Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Supernus Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Supernus Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Supernus Pharmaceuticals Inc. The current macd is -0.86051007.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Supernus price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Supernus. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Supernus price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Supernus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartSupernus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Supernus Pharmaceuticals Inc. The current adx is 21.86.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Supernus shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Supernus Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Supernus Pharmaceuticals Inc. The current sar is 30.04.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Supernus Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Supernus Pharmaceuticals Inc. The current rsi is 39.74. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Supernus Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartSupernus Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Supernus Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Supernus price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Supernus Pharmaceuticals Inc Daily Stochastic Oscillator ChartSupernus Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Supernus Pharmaceuticals Inc. The current cci is -126.24886467.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Supernus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartSupernus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Supernus Pharmaceuticals Inc. The current cmo is -20.20857805.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Supernus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartSupernus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Supernus Pharmaceuticals Inc. The current willr is -87.5.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Supernus Pharmaceuticals Inc Daily Williams %R ChartSupernus Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Supernus Pharmaceuticals Inc. The current atr is 0.6397474.

Supernus Pharmaceuticals Inc Daily Average True Range (ATR) ChartSupernus Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Supernus Pharmaceuticals Inc. The current obv is 1,394.

Supernus Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartSupernus Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Supernus Pharmaceuticals Inc. The current mfi is 42.14.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Supernus Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartSupernus Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Supernus Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-20 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-22 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-29 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-04 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-13 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-19 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-20 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-30 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-06 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-09 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-16 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-23 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-27 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-28 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-29 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-03 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-04 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-05 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-11 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-19 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-20 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-13 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-14 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-18 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-25 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-26 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-11 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Supernus Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Supernus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.735
Ma 20Greater thanMa 5029.190
Ma 50Greater thanMa 10031.384
Ma 100Greater thanMa 20033.454
OpenGreater thanClose27.800
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Supernus with someone you think should read this too:
  • Are you bullish or bearish on Supernus? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Supernus? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Supernus Pharmaceuticals Inc

I send you an email if I find something interesting about Supernus Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Supernus Pharmaceuticals Inc.

Receive notifications about Supernus Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.